Overview
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
Status:
Completed
Completed
Trial end date:
2009-04-01
2009-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Alexza Pharmaceuticals, Inc.Treatments:
Loxapine
Criteria
Inclusion Criteria:- nonsmoker subjects in good general health with normal spirometry at screening AND
baseline
Exclusion Criteria:
- history of asthma, COPD, or any other acute or chronic pulmonary disease or
bronchodilator use